Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

@article{Goetz2005EvidencebasedMR,
  title={Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004},
  author={Christopher G Goetz and Werner Poewe and Olivier Rascol and Cristina Sampaio},
  journal={Movement Disorders},
  year={2005},
  volume={20}
}
The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001–January 2004). Inclusion… 
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
TLDR
The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non‐motor symptoms and found that most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy.
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
TLDR
The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005 and highlights gaps for research.
Spinal cord stimulation for Parkinson’s disease: a systematic review
TLDR
Spinal cord stimulation appears to yield positive results for PD symptoms, especially for impairments in gait function and postural stability, however, evidence is limited and long-term prospective studies will be required to identify the optimal candidates for SCS and the best parameters of stimulation and to fully characterize the effects of stimulation on motor and nonmotor symptoms of PD.
Therapies in Parkinson's disease.
TLDR
This review examines currently available therapeutic strategies for Parkinson's disease, emphasizing evidence-based data as well as a patient-centered approach to the treatment of motor and nonmotor symptoms, and discusses the relative merits and disadvantages of delaying the initiation of levodopa therapy.
Effect of medical and surgical interventions on health‐related quality of life in Parkinson's disease
TLDR
It is found that unilateral pallidotomy, deep brain stimulation of the subthalamic nucleus, and rasagiline are efficacious to improve the HRQoL of PD patients.
The patient with Parkinson’s disease: Part I–Treating the motor symptoms; Part II–Treating the nonmotor symptoms
  • C. Snyder, C. Adler
  • Medicine, Psychology
    Journal of the American Academy of Nurse Practitioners
  • 2007
TLDR
Advances in the treatment for the motor and nonmotor symptoms of PD provide the clinician with increased options to improve the patient’s quality of life.
Parkinson disease: A summary of recent evidence-based medicine reviews
TLDR
EBM findings regarding treatment of the motor symptoms and the non-motor symptoms associated with PD are discussed and published guidelines, practice parameters, and Evidence Based Medicine reviews are reviewed.
Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
  • R. Bhidayasiri, H. Ling
  • Medicine, Biology
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • 2009
TLDR
Practical guidelines in the medical management of different types of motor complications are outlined in the present article according to what is available in Thailand, and surgical interventions should be reserved for patients with intractable motor complications after careful patient selection.
Treatment of early Parkinson's disease.
TLDR
This review summarizes currently available treatment options and treatment strategies, investigational treatments, and the importance of exercise for early Parkinson's disease and discusses recent studies focusing on exercise as an important component in the management of early Parkinsons disease.
Pharmacotherapy in Parkinson’s disease: case studies
TLDR
The treatment management of three case studies illustrating different stages of disease with distinct phenomenology are discussed, and the proposed therapeutic alternatives are discussed based on the best data available; that is, treatment guidelines, clinical trial results or observational data.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Management of Parkinson's disease: An evidence‐based review
  • A. Lang, A. Lees
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2002
TLDR
A systematic review of the literature dealing with the efficacy and safety of available treatments aimed at identifying those treatments for which there is sound scientific support to justify their application and to highlight where a lack of evidence points to the need for future clinical trials.
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease
TLDR
Following surgery, patients' showed improvement in all the cardinal motor signs of PD including tremor, rigidity, bradykinesia, gait and balance and drug‐induced dyskinesias were also markedly improved.
Anticholinergics for symptomatic management of Parkinson's disease.
TLDR
As monotherapy or as an adjunct to other antiparkinsonian drugs, anticholinergics are more effective than placebo in improving motor function in Parkinson's disease.
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
TLDR
Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
TLDR
Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on results, and Stratification based on disease severity showed a treatment effect in milder patients.
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)
TLDR
Entacapone is an effective and safe levodopa extender and enhancer, improving the symptomatic efficacy of levodOPA in PD and adding to the patients' benefit.
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
TLDR
Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F‐dopa PET, and this prospective, 2‐year, randomized, double‐blind, multinational study compared the rates of loss of dopamine‐terminal function in de novo patients with clinical and 18F-dopaPET evidence of early PD.
Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
The Unified Parkinson's Disease Rating Scale (UPDRS) is primarily composed of an investigator‐derived objective rating of motor function and a patient‐derived assessment of activities of daily living
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study
TLDR
A 6‐month oral administration of 150 mg/day piribedil in combination with L‐dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients.
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study
TLDR
It is demonstrated that entacapone provides additional antiparkinsonian benefits tolevodopa therapy and is well tolerated in levodopa-treated PD patients experiencing wearing-off motor fluctuations despite adjunct dopamine agonist therapy.
...
1
2
3
4
5
...